Gefitinib, erlotinib and imatinib are a therapeutic class of tyrosine kinase inhibitors (TKIs) that significantly reduce tyrosine kinase activity by inhibiting its phosphorylation level and are important treatment options in patients with tyrosine kinase-driven malignancies, including epidermal growth factor receptor (EGFR) mutated non-small-cell lung cancer (NSCLC) and breakpoint cluster region-Abelson oncogene 1(Bcr-Abl1), non-receptor tyrosine kinase-driven chronic myeloid leukemia (CML)1, 2, 3. This evidence concerns the gene NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive.